Solstice Oncology Deal History & Licensing Activity
Solstice Oncology is a life sciences. Over the past three years, Solstice Oncology has been involved in 1 licensing and acquisition transaction, with a primary focus on Antibodies (2 deals).
Deals (12mo)
2
Active Trials
0
Top Modality
Antibodies
Focus Area
Oncology
Solstice Oncology Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Solstice Oncology in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| porustobart (HBM-4003) | Harbour Biomed | Antibodies | Unknown | license | Feb 2026 |
Solstice Oncology Pipeline Focus
Therapeutic areas and modalities where Solstice Oncology is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Solstice Oncology Strategic Signals
Key indicators of Solstice Oncology's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
See How Your Asset Matches Solstice Oncology's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Oncology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for antibodies deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Solstice Oncology Licensing & Deal Activity
Solstice Oncology is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 1 deal over the past three years, Solstice Oncology ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Solstice Oncology include Oncology (2 deals and trials). In terms of modality, Solstice Oncology has shown particular interest in antibodies.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Solstice Oncology and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Solstice Oncology's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.